Categories
Zydus Lifesciences Limited — Updates, 25-04-2026: Press Release
25-04-2026 · 12:49 pm
Zydus received approval to begin Phase III trials for Zintrodiazine, a novel anti-malarial drug. This candidate is active against drug-resistant strains of P. falciparum and P. vivax, addressing a critical unmet healthcare need.
No comments yet. Be the first to comment!